News Headlines Article

At $1,000 a pill, Sovaldi will bankrupt us
San Francisco Chronicle

How much can we afford to pay for one drug? How much profit does one company deserve for producing that drug? With last month’s release of record earnings for Gilead Sciences – nearly $6 billion in profits in half a year from the hepatitis C drug, Sovaldi –  these questions need to be answered.

The $1,000-a-pill price for Sovaldi makes plain that our system for pricing prescription drugs is broken. At more than $84,000 for a full course of treatment, the total cost of treating the estimated 3.2 million Americans living with chronic Hepatitis C is about $270 billion – almost as much as the United States spends annually on all other prescription drugs combined.

Commands